Filing Analysis
Atara Biotherapeutics announced the appointment of Brian Cherry to its Board of Directors and Audit Committee, and reported the results of its 2026 Annual Meeting of Stockholders.
📋 Key Facts
- Brian Cherry appointed as Class I director and member of the Audit Committee effective June 11, 2026.
- Mr. Cherry received an initial equity award of 24,000 restricted stock units vesting over three years.
- Mr. Cherry will receive an annual cash retainer of $55,000.
- Stockholders elected AnhCo Nguyen Ph.D. and Nachi Subramanian to the Board until 2029.
- Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase reserved common stock by 400,000 shares.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Atara Biotherapeutics announced its financial results for the first quarter ended March 31, 2026, and provided an update on operational progress.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 12, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes Exhibit 99.1, a press release titled 'Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress'.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Atara Biotherapeutics provided a regulatory update following a Type A meeting with the FDA regarding the Complete Response Letter (CRL) for its EBVALLO™ Biologics License Application. The meeting aimed to address issues raised by the FDA in the CRL issued on January 9, 2026.
🚩 Red Flags
- The company is currently managing a Complete Response Letter (CRL), which signifies a failure to obtain FDA approval in the initial review cycle.
- Regulatory delays for lead assets can significantly impact the cash runway of micro-cap biotech companies.
📋 Key Facts
- The company held a Type A meeting with the FDA to discuss the CRL for tabelecleucel (EBVALLO™).
- The CRL was originally issued by the FDA on January 9, 2026.
- The update was communicated via a press release on May 7, 2026.
- EBVALLO™ is a primary product candidate for the company.
Atara Biotherapeutics received a notice from Nasdaq on April 30, 2026, for failing to maintain the minimum $50 million market value of listed securities (MVLS) required for the Nasdaq Global Select Market. The company has 180 days, until October 27, 2026, to regain compliance by maintaining a $50 million MVLS for at least 10 consecutive business days.
🚩 Red Flags
- Market capitalization has fallen below the $50 million threshold for a sustained period (30 days).
- Potential for delisting from the Nasdaq Global Select Market if compliance is not regained.
- The notice reflects a significant decline in the company's equity valuation.
📋 Key Facts
- Notice received from Nasdaq on April 30, 2026, regarding non-compliance with Nasdaq Listing Rule 5450(b)(2)(A).
- The Company's market value of listed securities (MVLS) was below $50 million for 30 consecutive business days.
- The compliance deadline to regain the $50 million MVLS threshold is October 27, 2026.
- To regain compliance, MVLS must close at $50 million or more for a minimum of 10 consecutive business days.
- The Company is considering options including a transfer to The Nasdaq Capital Market.
Atara Biotherapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release furnished as Exhibit 99.1.
📋 Key Facts
- Financial results announced on March 16, 2026, for the fiscal year ended December 31, 2025.
- The filing includes Item 2.02 for Results of Operations and Financial Condition.
- The press release is titled 'Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress'.
- Yanina Grant-Huerta, Chief Accounting Officer, signed the report.
Atara Biotherapeutics announced that the FDA has scheduled a Type A meeting to discuss the Complete Response Letter (CRL) issued on January 9, 2026, regarding the Biologics License Application (BLA) for tabelecleucel (tab-cel). The meeting, conducted with partner Pierre Fabre Pharmaceuticals, aims to resolve issues raised in the CRL and establish a path for BLA resubmission.
🚩 Red Flags
- The underlying cause of this filing is a Complete Response Letter (CRL), which represents a formal FDA rejection of the current BLA.
- The requirement for 'additional efficacy data' suggests the initial clinical data package was insufficient for approval.
- The company is reliant on a third-party partner (Pierre Fabre) to lead the regulatory interaction.
📋 Key Facts
- The FDA scheduled a Type A meeting to discuss the CRL for tabelecleucel (tab-cel) issued on January 9, 2026.
- The BLA is held by Atara's partner, Pierre Fabre Pharmaceuticals.
- The meeting will focus on addressing CRL points and incorporating additional efficacy data collected since the original submission.
- Atara expects to provide a further regulatory update in the second quarter of 2026.
- Tab-cel (EBVALLO) is an allogeneic T-cell immunotherapy targeting EBV+ PTLD.
Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, has requested a Type A meeting with the FDA to address issues raised in a January 2026 Complete Response Letter (CRL) for EBVALLO™.
🚩 Red Flags
- The FDA previously issued a Complete Response Letter (CRL) on January 9, 2026, which is a formal rejection of the current application.
- Type A meetings are typically reserved for stalled product development or to discuss critical path issues, indicating significant regulatory hurdles.
📋 Key Facts
- Pierre Fabre Pharmaceuticals submitted a request for a Type A meeting with the FDA on March 3, 2026.
- The meeting aims to discuss the plan to address issues from the CRL issued by the FDA on January 9, 2026.
- The regulatory update concerns the Biologics License Application (BLA) for Tabelecleucel (EBVALLO™).
- The filing is categorized under Item 8.01 (Other Events).
Atara Biotherapeutics (ATRA) filed an 8-K on February 23, 2026 disclosing an amendment to its Purchase and Sale Agreement with HCR Molag Fund, L.P., deferring a $9.0 million milestone payment obligation from June 30, 2026 to January 1, 2028. In exchange for this deferral, the Company issued HCR a warrant to purchase up to 400,000 shares of common stock at a near-zero exercise price of $0.0001 per share, representing a significant equity concession. The filing covers three 8-K items simultaneously, suggesting financial pressure and a need for near-term cash relief.
🚩 Red Flags
- Near-zero exercise price warrant ($0.0001/share) issued to a creditor/financial partner signals the company lacked cash or alternative leverage to negotiate better terms
- Inability to meet a $9.0 million milestone payment by June 30, 2026 implies potential liquidity stress — requiring an 18-month extension
- Multiple 8-K items in a single filing (1.01, 3.02, 8.01) is a red flag escalator per analytical guidelines
- Issuance of unregistered equity securities (Item 3.02) to a lender/fund in exchange for debt relief raises related-party and dilution concerns
- Warrant has no expiration date, creating permanent dilution overhang of up to 400,000 shares
- HCR Molag Fund relationship spans back to 2022 Purchase and Sale Agreement, suggesting ongoing financial entanglement with a single capital provider
📋 Key Facts
- Amendment dated February 20, 2026 to the Purchase and Sale Agreement originally dated December 20, 2022 with HCR Molag Fund, L.P.
- $9.0 million cash milestone payment due date extended from June 30, 2026 to January 1, 2028 — an 18-month deferral
- Milestone is tied to the Amended and Restated Commercialization Agreement dated October 31, 2023 with Pierre Fabre Medicament
- Company issued a warrant to purchase up to 400,000 shares of Common Stock as consideration for the deferral
- Warrant exercise price: $0.0001 per share (effectively a free equity grant)
- Warrant is exercisable immediately with no expiration date
- Beneficial ownership blocker at 4.99% of outstanding shares
- Warrant may be exercised via cashless exercise
- Warrant issued under Section 4(a)(2) exemption (unregistered); Company intends to file a registration statement for resale
- Filing covers Items 1.01, 3.02, and 8.01 — three separate items in a single 8-K
- Signed by AnhCo Thieu Nguyen, President and CEO